Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|February 2, 2015
- Pharmaceutical Technology-02-02-2015
- Volume 39
- Issue 2
FANUC Robot Enhances Cycles Per Second
FANUC’s M-1iA delta robot is designed for bottling lines with the capability of operating at 120 cycles per second.
FANUC’s M-1iA delta robot is designed for bottling lines with the capability of operating at 120 cycles per second. Program selections can be selected via robot controller, enabling ten variants of the bottle to be run on the system.
An integrated solution to enhance vision capabilities, iRVision, eliminates the need for third-party software. Another solution, iRVision 2D, includes part location, barcode reading, and anti-defect checking, while iRPickTool can be included for picking and placing bottles on conveyors.
FANUC
Articles in this issue
over 11 years ago
Hiden Analytical Combination Spectrometer Increases Repeatabilityover 11 years ago
Ross Disperser Maintains Consistencyover 11 years ago
Radio Frequency Dryer Improves Efficiencyover 11 years ago
Preventing Tablet Tooling Problemsover 11 years ago
Chiral Resolution with and without Resolving Agentsover 11 years ago
FDA Sets Agenda for 2015 Guidance Developmentover 11 years ago
Cures Require Compromiseover 11 years ago
Ligand-Binding Assays and the Determination of Biosimilarityover 11 years ago
Labeling of Biosimilarsover 11 years ago
FDA Sets Policies to Enhance Drug Security and SafetyRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5